drugset / Trial / NCT05276401
Nu-3 Topical Gel for Treatment of Diabetic Foot Ulcer
Phase 2
Terminated
3 enrolled
Lakewood-Amedex Inc
PrimeVigilance · collabProfessional Education and Research Institute · collab
RandomizedSequentialQuadruple-blindTreatment
Summary
A PHASE 2a, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED DOSE ESCALATING STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TOPICALLY APPLIED BISPHOSPHOCIN NU-3 GEL TO CLINICALLY NONINFECTED CHRONIC DIABETIC FOOT ULCERS (cDFU)
Timeline
- Start
- 2022-03-11
- Primary completion
- 2022-05-18
- Completion
- 2022-06-15
Outcome
Outcome not reported
Stopped: “Request for additional preclinical data.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nu-3 | Unknown | 5 % | Topical |
| Subject | Nu-3 | Unknown | 10 % | Topical |